Abstract
Background
Clozapine is the most effective medication for treatment-refractory schizophrenia. However, it has a high burden of adverse events, including common adverse events such as sialorrhea. Sialorrhea can lead to severe physical complications such as aspiration pneumonia, as well as psychological complications including embarrassment and low self-esteem. Compromised adherence and treatment discontinuation can occur due to intolerability. There have been no meta-analyses examining strategies to mitigate clozapine-induced sialorrhea.
Methods
We systematically searched Chinese and Western research databases for randomised controlled trials examining agents for clozapine-induced sialorrhea. No limit to language or date were applied to the search. Where sufficient data for individual agents was available, pairwise meta-analyses were conducted. Results were provided as risk ratios and number needed to treat. Sensitivity analysis was conducted by study quality. Adverse events were provided as number needed to harm.
Results
19 studies provided data for use in the meta-analysis. Improvement in clozapine-induced sialorrhea was seen in meta-analyses of propantheline (studies = 6, risk ratio [RR] 2.38, 95% confidence interval [CI] 1.52–3.73; number needed to treat [NNT] 3, 95% CI 1.9–2.7), diphenhydramine (studies = 5, RR 3.09, 95% CI 2.36–4.03; NNT 2, 95% CI 1.5–2.0), chlorpheniramine (studies = 2, RR 2.37, 95% CI 1.59–3.55; NNT 3, 95% CI 1.6–3.5), and benzamide derivatives (odds ratio [OR] 6.93, 95% CI 3.03–15.86). When meta-analyses were limited to high-quality studies, all these results remained significant. Single studies of benzhexol, cyproheptadine, doxepin and Kongyan Tang showed promise. Propantheline increased rates of constipation with a number needed to harm (NNH) of 9 (95% CI 4.2–204.1).
Conclusion
Clozapine-induced sialorrhea is a potentially serious adverse event. Included studies in this meta-analysis were limited by poor study quality. Diphenhydramine, chlorpheniramine and benzamide derivatives appear to have the best supporting evidence and lowest reported adverse events. Caution should be exercised when using propantheline given its increased risk of constipation.
Similar content being viewed by others
References
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
Howes OD, McCutcheon R, Agid O, De Bartolomeis A, Van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2016;174(3):216–29.
Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–92.
Land R, Siskind D, Mcardle P, Kisely S, Winckel K, Hollingworth SA. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand. 2017;135(4):296–309.
Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138(2):101–9.
Rohde C, Polcwiartek C, Kragholm K, Ebdrup B, Siskind D, Nielsen J. Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. Acta Psychiatrica Scandinavica. 2018;137(1):47–53.
Maher S, Cunningham A, O’Callaghan N, Byrne F, Mc Donald C, McInerney S, et al. Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol. 2016;6(3):178–84. https://doi.org/10.1177/2045125316641019.
Bird AM, Smith TL, Walton AE. Current treatment strategies for clozapine-induced sialorrhea. Ann Pharmacother. 2011;45(5):667–75. https://doi.org/10.1345/aph.1P761.
Citrome L, McEvoy JP, Saklad SR. A guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses. 2016. https://doi.org/10.3371/csrp.saci.070816.
Liang C-S, Ho P-S, Shen L-J, Lee W-K, Yang F-W, Chiang K-T. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res. 2010;119(1–3):138–44. https://doi.org/10.1016/j.schres.2010.02.1060.
Sagya R, Weizman A, Katz N. Pharmacological and behavioral management of some often-overlooked clozapine-induced side effects. Int Clin Psychopharmacol. 2014;29(6):313–7. https://doi.org/10.1097/YIC.0000000000000044.
Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2009;70(8):1114–9. https://doi.org/10.4088/JCP.08m04495.
Ekström J, Godoy T, Loy F, Riva A. Parasympathetic vasoactive intestinal peptide (VIP): a likely contributor to clozapine-induced sialorrhoea. Oral Dis. 2014;20(3):e90–6. https://doi.org/10.1111/odi.12139.
Ignjatović Ristić D, Cohen D, Obradović A, Nikić-Đuričić K, Drašković M, Hinić D. The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. Nord J Psychiatry. 2018;72(2):124–9. https://doi.org/10.1080/08039488.2017.1400097.
Villa A, Wolff A, Narayana N, Dawes C, Aframian D, Lynge Pedersen A, et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Dis. 2016;22(5):365–82. https://doi.org/10.1111/odi.12402.
Reinstein MJ, Sirotovskaya LA, Chasanov MA, Jones LE, Mohan S. Comparative efficacy and tolerability of benzatropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clin Drug Investig. 1999;17(2):97–102.
Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, et al. Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev. 2008;3:Cd005579. https://doi.org/10.1002/14651858.cd005579.pub2.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. https://doi.org/10.1186/2046-4053-4-1.
Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2011. http://handbook.cochrane.org.
Barendregt JJ, Doi SA. MetaXL user guide version 5.3. EpiGear International Pty Ltd; 2016.
Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006;21(2):99–103.
Kreinin A, Miodownik C, Mirkin V, Gaiduk Y, Yankovsky Y, Bersudsky Y, et al. Double-blind, randomized, placebo-controlled trial of metoclopramide for hypersalivation associated with clozapine. J Clin Psychopharmacol. 2016. https://doi.org/10.1097/jcp.0000000000000493.
Man W, Colen-de KJ, Schulte P, Cahn W, Haelst I, Doodeman H, et al. The effect of glycopyrrolate on nocturnal sialorrhea in patients using clozapine: a randomized, crossover, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2017. https://doi.org/10.1097/jcp.0000000000000657.
Xu H, Dong A, Zhang T, Shu W. Diphenhydramine for clozapine -induced salivation at various dosage levels. New Drugs Clin Rem. 1997;16(04):14–6.
Yang S, Shundi X, Yin Y. A double-blinded placebo-controlled trial on the use of cyproheptadine in clozapine-induced sialorrhoea. Chin J Neuropsychiatr Disord. 1996;08(01):12–3.
Lin H. A double-blinded placebo-controlled trial on the use of propantheline in clozapine-induced sialorrhoea. Chin J Neuropsychiatr Dis. 1999;25(05):316–7.
Yang H, Huang S, Feng C, Chen J. A study on the treatments for clozapine-induced sialorrhoea. J Binzhou Med Coll. 1999;22(05):451.
Gong G, Yuan L, Qin D, Li H, Zhao L, Hu C, et al. A double-blinded placebo-controlled randomized trial on the use of diphenhydramine, propantheline and astemizole in clozapine-induced sialorrhoea. Chin J Psychiatry. 1998;31(03):10.
Tao J, Yin X, Liu J. A randomized controlled trial on the use of sulpiride in clozapine-induced sialorrhoea. Neurol Disord Ment Health. 2007;07(02):141–3.
Qin J, Cui C, Ge F. A comparison of treatments for clozapine-induced sialorrahoea. Chin J Clin Psychiatry. 1999;09(04):225–6.
Fan Z, Zheng C, Li S. A placebo-controlled trial on the use of propantheline in clozapine-induced sialorrhoea. Strait Pharm J. 1996;08(02):33–4.
Cheng J, Jiang S. A study on the use of benzhexol in clozapine-induced sialorrhoea. J Mod Chin Integr Med. 2005;14(16):2135–6.
Zhao Z, Chen H, Xie B, Sun S, Wu H, Ma Q, et al. A controlled trial on the use of Zhiyan capsule in clozapine-induced sialorrhoea. Med J Chin Civ Admin. 2000;12(02):34–5.
Lu X, Xue S, Yang M. The use of diphehydramine in clozapine-induced sialorrhoea. Sichuan J Ment Health. 1998;11(01):38–40.
Lu L, Liu G, Zhao J, Liu A, Liu S, Liu L, et al. A double-blinded placebo-controlled trial on the use of chlorpheniramine in clozapine-induced sialorrhoea. Chin J Neuropsychiatr Dis. 1994;27(04):252–3.
Li Z, Song Z, Cheng P, Li C, Xiang X, Shi H. A double-blinded controlled trial on the use of astemizole in clozapine-induced sialorrhoea. Chin J Clin Psychiatry. 1993;03(01):34–5.
Mao Z, Yang Y, Wang Y, Ma J, Cheng J. A controlled trial on the use of traditional chinese medication Kongyan Decoction in clozapine-induced sialorrhoea. In: The 12th national academic conference on integrated traditional Chinese medicine and western medicine in Psychiatry. Lanzhou, Gansu, China. 2013.
Qian Q, Gao Z. The use of topical Wu Dan San on acupuncture points inclozapine-induced sialorrhoea. Shanghai Arch Psychiatry. 1996;08(02):103.
Ekström J, Godoy T, Riva A. Clozapine: agonistic and antagonistic salivary secretory actions. J Dent Res. 2010;89(3):276–80. https://doi.org/10.1177/0022034509356055.
Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry. 1996;40(11):1132–4. https://doi.org/10.1016/s0006-3223(96)89255-9.
Webber MA, Szwast SJ, Steadman TM, Frazer A, Malloy FW, Lightfoot JD, et al. Guanfacine treatment of clozapine-induced sialorrhea. J Clin Psychopharmacol. 2004;24(6):675–6.
BenAryeh H, Jungerman T, Szargel R, Klein E, Laufer D. Salivary flow-rate and composition in schizophrenic patients on clozapine, subjective reports and laboratory data. Biol Psychiatry. 1996;39(11):946–9. https://doi.org/10.1016/0006-3223(95)00296-0.
Antonello C, Tessier P. Clozapine and sialorrhea: a new intervention for this bothersome and potentiallydangerous side effect. J Psychiatry Neurosci. 1999;24(31):250.
Sharma A, Ramaswamy S, Dahl E, Dewan V. Intraoral application of atropine sulfate ophthalmic solution for clozapine-induced sialorrhea. Ann Pharmacother. 2004;38(9):1538.
Comley C, Galletly C, Ash D. Use of atropine eye drops for clozapine induced hypersalivation. Aust N Z J Psychiatry. 2000;34(6):1033–4.
Gaftanyuk O, Trestman R. Scopolamine patch for clozapine-induced sialorrhea. Psychiatr Serv. 2004;55(3):318.
McKane J, Hall C, Akram G. Hyoscine patches in clozapine-induced hypersalivation. Psychiatr Bull. 2001;25(7):277.
Canaday BR, Stanford RH. Propantheline bromide in the management of hyperhidrosis associated with spinal cord injury. Ann Pharmacother. 1995;29(5):489–92. https://doi.org/10.1177/106002809502900507.
Duggal H. Glycopyrrolate for clozapine-induced sialorrhea. Prog Neuro Psychopharmacol Biol Psychiatry. 2007;31:1546–7.
MIMS. MIMS online. Crows Nest, N.S.W: monthly index of medical specialities Australia; 1996.
Parfitt K, Martindale W. Martindale: the complete drug reference. London: Pharmaceutical Press; 1999.
Matsumoto S, Yamazoe Y. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol. 2001;51(2):133–42.
WHO. Astemizole: voluntary withdrawal: Janssen, USA. WHO Pharmaceuticals Newsletter. 1999.
Caldara R, Masci E, Cambielli M, Tittobello A, Piepoli V, Barbieri C. Effect of sulpiride isomers on gastric acid and gastrin secretion in healthy man. Eur J Clin Pharmacol. 1983;25(3):319–22.
Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: a review of treatment strategies. Can J Psychiatry. 2007;52(6):377–84. https://doi.org/10.1177/070674370705200607.
Siskind DJ, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B, Kisely S. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;52:751–67.
Cohen JF, Korevaar DA, Wang J, Spijker R, Bossuyt PM. Should we search Chinese biomedical databases when performing systematic reviews? Syst Rev. 2015;4:23. https://doi.org/10.1186/s13643-015-0017-3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Dan Siskind is supported in part by an NHMRC ECF APP1111136. The authors have no other funding to disclose.
Conflict of interest
Shih-Yu Chen, Gopi Ravindran, Qichen Zhang, Steve Kisely and Dan Siskind declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chen, SY., Ravindran, G., Zhang, Q. et al. Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis. CNS Drugs 33, 225–238 (2019). https://doi.org/10.1007/s40263-019-00612-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-019-00612-8